晚期膀胱癌PD-1/PD-L1抑制剂治疗的研究进展

Abstract
Figure/Table
References (29)
Related Citation (5)

Download: PDF (619 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Bladder cancer is a common cancer in the urinary system. The current common treatments include surgery and chemotherapy. However, the efficacy of patients with advanced bladder cancer is still unsatisfactory. In recent years, with the advent of immunotherapy represented by immunological checkpoint inhibitors such as programmed cell death 1 (PD-1)/programmed cell death ligation 1 (PD-L1) inhibitors, new treatments for advanced bladder cancer have emerged. PD-1/PD-L1 inhibitors block PD-1/PD-L1 binding, thereby blocking negative immune regulatory signals, then enhancing anti-tumor immune activity. This article will review the principles, current status and adverse effects of PD-1/PD-L1 inhibitors in the treatment of advanced bladder cancer through analyzing data and results in clinical trials, and provide assistance for the clinical treatment of patients with advanced bladder cancer.

Key words： Advanced bladder cancer Programmed cell death 1/programmed cell death ligation 1 inhibitor Immunological checkpoint inhibitor Immunotherapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yanze WANG Lei CHEN Zhiyuan LIU Xiuheng

Cite this article:

LI Yanze WANG Lei CHEN Zhiyuan LIU Xiuheng. Research progress of PD-1/PD-L1 inhibitors for the treatment of advanced bladder cancer[J]. 中国医药导报, 2020, 17(4): 40-43,51.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I4/40

[1] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[2] Kim J. Immune checkpoint blockade therapy for bladder cancer treatment [J]. Investig Clin Urol，2016，57（Suppl 1）：S98-S105.
[3] Postow MA，Callahan MK，Wolchok JD. Immune checkpoint blockade in cancer therapy [J]. J Clin Oncol，2015，33（17）：1974-1982.
[4] Siefker-Radtke AO，Apolo AB，Bivalacqua TJ，et al. Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma [J]. J Urol，2018，199（5）：1129-1142.
[5] Sundararajan S，Vogelzang NJ. Anti-PD-1 and PD-L1 therapy for bladder cancer：what is on the horizon? [J]. Future Oncol，2015，11（16）：2299-2306.
[6] Koshkin VS，Grivas P. Emerging role of immunotherapy in advanced urothelial carcinoma [J]. Curr Oncol Rep，2018， 20（6）：48.
[7] Ning YM，Suzman D，Maher VE，et al. FDA approval summary：Atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy [J]. Oncologist，2017，22（6）：743-749.
[8] Herbst RS，Soria JC，Kowanetz M，et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J]. Nature，2014，515（7528）：563-567.
[9] Petrylak D，Powles T，Bellmunt J，et al. Atezolizumab（atezo）in patients with metastatic urothelial carcinoma（mUC）：a 2-year clinical update from a phase Ⅰa study [J]. J Clin Oncol，2017，35（6 Suppl）：290.
[10] Rosenberg JE，Hoffman-censits J，Powles T，et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy：a single-arm， multicentre，phase 2 trial [J]. Lancet，2016，387（10031）：1909-1920.
[11] Powles T，Durán I，van der Heijden MS，et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma（IMvigor211）：a multicentre，open-label，phase 3 randomised controlled trial [J]. Lancet，2017，S0140673 61733297X：1-11.
[12] Brahmer JR，Hammers H，Lipson EJ. Nivolumab：targeting PD-1 to bolster antitumor immunity [J]. Future Oncol，2015，11（9）：1307-1326.
[13] Sharma P，Callahan MK，Bono P，et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma （CheckMate 032）：a multicentre，open-label，two-stage，multi-arm，phase 1/2 trial [J]. Lancet Oncol，2016，17（11）：1590-1598.
[14] Sharma P，Retz M，Siefker-radtke A，et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy （CheckMate 275）：a multicentre，singlearm，phase 2 trial [J]. Lancet Oncol，2017，18（3）：312-322.
[15] Raggi D，Miceli R，Sonpavde G，et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer：a systematic review and meta-analysis [J]. Ann Oncol，2016，27（1）：49-61.
[16] Massard C，Gordon MS，Sharma S，et al. Safety and efficacy of Durvalumab（MEDI4736），an anti-programmed cell death Ligand-1 immune checkpoint inhibitor，in patients with advanced Urothelial bladder cancer [J]. J Clin Oncol，2016，34（26）：3119-3125.
[17] Hahn NM，Powles T，Massard C，et al. Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma（UC）[J]. J Clin Oncol，2017，35（15 Suppl）：4525.
[18] Powles T，O′donnell PH，Massard C，et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma：updated results from a phase 1/2 open-label study [J]. JAMA Oncol，2017，3（9）：e172411.
[19] Powles T，O′donnell PH，Massard C，et al. Updated efficacy and tolerability of durvalumab in locally advanced and metastatic urothelial carcinoma [J]. J Clin Oncol，2017， 35（6 Suppl）：286.
[20] Heery CR，O′sullivan coyne GH，Madan RA，et al. Phase Ⅰ open-label，multiple ascending dose trial of MSB0010 718C，an anti-PD-L1 monoclonal antibody in advanced solid malignancies [J]. J Clin Oncol，2014，32（15 Suppl）：3064.
[21] Boyerinas B，Jochems C，Fantini M，et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab（MSB0010718C）on human tumor cells [J]. Cancer Immunol Res，2015，3（10）：1148-1157.
[22] Grenga I，Donahue RN，Lepone LM，et al. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses [J]. Clin Transl Immunol，2016，5（5）：e83.1-e83.12.
[23] Heery CR，O′sullivan-coyne G，Madan RA，et al. Avelumab for metastatic or locally advanced previously treated solid tumors（JAVELIN Solid Tumor）：a phase 1a，multicohort，dose-escalation trial [J]. Lancet Oncol，2017，18（5）：587-598.
[24] Apolo AB，Infante JR，Balmanoukian A，et al. Avelumab，an anti-programmed death-ligand 1 antibody，in patients with refractory metastatic urothelial carcinoma：results from a multicenter，phase Ⅰb study [J]. J Clin Oncol，2017，35（19）：2117-2124.
[25] Khoja L，Butler MO，Kang SP，et al. Pembrolizumab [J]. J Immuno Ther Cancer，2015，3（1）：36.
[26] Bellmunt J，De wit R，Vaughn DJ，et al. KEYNOTE-045 investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma [J]. New Engl J Med，2017，376（11）：1015-1026.
[27] Michot JM，Bigenwald C，Champiat S，et al. Immune-related adverse events with immune checkpoint blockade：a comprehensive review [J]. Eur J Cancer，2016，54：139-148.
[28] Weber JS，Kahler KC，Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab [J]. J Clin Oncol，2012，30（21）：2691-2697.
[29] Champiat S，Lambotte O，Barreau E，et al. Management of immune checkpoint blockade dysimmune toxicities：a collaborative position paper [J]. Ann Oncol，2015，27（4）：559-574.